Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30961552 | 1.00 | GRIK1 (0.50) | GRIK1FLT1FLT4KDRKMT2A | |
| SCHEMBL4215245 | 0.90 | JAK2 (0.49) | GRIK1KMT2AGAASMN1; SMN2NPC1 | |
| SCHEMBL30961556 | 0.84 | GRIK1 (0.50) | GRIK1KMT2AGAASMN1; SMN2NPC1 | |
| SCHEMBL14024175 | 0.84 | NPC1 (0.47) | FLT1FLT4KDRKMT2AGAA | |
| SCHEMBL24238348 | 0.84 | GRIK1 (0.50) | GRIK1KMT2AGAASMN1; SMN2NPC1 | |
| SCHEMBL28567907 | 0.83 | NPC1 (0.51) | GRIK1FLT1FLT4KDRKMT2A | |
| SCHEMBL1753321 | 0.81 | JAK2 (0.68) | GRIK1FLT1FLT4KDRKMT2A | |
| SCHEMBL28582168 | 0.81 | KMT2A (0.43) | GRIK1KMT2AGAASMN1; SMN2NPC1 | |
| SCHEMBL4511425 | 0.80 | P2RX1 (0.53) | GRIK1KMT2ALMNAALDH1A1JAK2 | |
| SCHEMBL4517016 | 0.80 | KCNH2 (0.64) | GRIK1FLT1FLT4KDRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234928-A1 | Novel Compounds for Treating Fibrosis and Inflammatory Conditions | MAKSCIENTIFIC, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234928-A1 | Novel Compounds for Treating Fibrosis and Inflammatory Conditions | MAKSCIENTIFIC, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234928-A1 | Novel Compounds for Treating Fibrosis and Inflammatory Conditions | MAKSCIENTIFIC, LLC | 2023-07-27 | — | — | US | disclosed |
| WO-2022026478-A1 | NOVEL COMPOUNDS FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS | MAKSCIENTIFIC, LLC (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022026478-A1 | NOVEL COMPOUNDS FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS | MAKSCIENTIFIC, LLC (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220033393-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2022-02-03 | — | — | US | disclosed |
| US-8853205-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2014-10-07 | — | — | US | disclosed |
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-8410097-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120095047-A1 | Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors | UNIVERSITY OF CONNECTICUT (US) | 2012-04-19 | — | — | US | disclosed |
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. | 2009-07-16 | — | — | US | disclosed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | disclosed |
| EP-1845972-A2 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINIOD RECEPTORS | University of Connecticut (US) | 2007-10-24 | — | — | EP | disclosed |
| US-7109216-B2 | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| WO-2006074445-A2 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINIOD RECEPTORS | MAKRIYANNIS ALEXANDROS (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-03-10 | — | — | US | disclosed |
| CN-1556703-A | With CB1Agonistic activity, CB1Partial agonist Activity or CB11H-imidazole derivatives with antagonistic activity | ������ҩ������˾ | 2004-12-22 | — | — | CN | disclosed |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
| EP-1438296-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003027076-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | CNR1, CNR2, CHRM1 | GRIK1 155/4885FLT1 1462/4885FLT4 2641/4885 |
| US-20220033393-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | CNR1, CNR2, OPRM1 | GRIK1 1166/4885FLT1 2457/4885FLT4 3507/4885 |
| US-20120095047-A1 | Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors | CNR2, CNR1, GPR18 | GRIK1 531/4885FLT1 3306/4885FLT4 2509/4885 |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | CNR1, CNR2, CHRM1 | GRIK1 198/4885FLT1 1297/4885FLT4 2336/4885 |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | CNR1, CNR2, HRH4 | GRIK1 207/4885FLT1 1657/4885FLT4 2684/4885 |
| US-20230234928-A1 | Novel Compounds for Treating Fibrosis and Inflammatory Conditions | CNR2, CNR1, GPR174 | GRIK1 2457/4885FLT1 1760/4885FLT4 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.